Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
July 11, 2023 14:38 ET
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
July 11, 2023 14:31 ET
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease
July 06, 2023 14:37 ET
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Five Liters, a Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to...
Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal
January 17, 2023 12:47 ET
|
Spark Biomedical
GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss
June 02, 2022 11:00 ET
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation solutions, announced today a collaboration with The Feinstein Institutes for...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
March 03, 2022 11:22 ET
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment
November 16, 2021 11:00 ET
|
Spark Biomedical
Dallas, TX, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. has been helping patients overcome acute opioid withdrawal using its Sparrow Therapy System — Transcutaneous Auricular...
Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients
November 04, 2021 10:25 ET
|
Spark Biomedical
Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....
Sierra Tucson Combats Opioid Withdrawal Using Groundbreaking Wearable Neurostimulation Therapy
May 26, 2021 11:19 ET
|
Spark Biomedical
TUCSON, AZ, May 26, 2021 (GLOBE NEWSWIRE) -- Sierra Tucson, a nationally respected provider of comprehensive residential services for adults struggling with substance use disorders and other...
Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System
February 03, 2021 15:34 ET
|
Spark Biomedical
Danville, KY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Dr. Anjum Bux, a leading expert in pain management, was the first in the nation to successfully treat commercial patients using Transcutaneous...